Chinese clinical-stage biopharmaceutical firm Gracell Biotechnologies Inc. has completed a $100 million Series C round co-led by the US investment company Wellington Management, New York-based OrbiMed Healthcare Fund Management, and VC firm 5Y Capital (formerly Morningside Venture Capital), the investee company said on Wednesday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
